Indian pharma maker of branded formulations, APIs and CDMO; a top-5 global lozenges manufacturer.
Price
Market Cap
Sector
Healthcare
Rank
| Line item | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 | FY26 |
|---|---|---|---|---|---|---|---|---|
| LiabilitiesEquity Capital | 15 | 15 | 15 | 15 | 16 | 16 | 16 | 16 |
| Reserves | 1.4k | 1.8k | 2.1k | 2.5k | 2.9k | 3.4k | 3.8k | 4.1k |
| Borrowings | 29 | 45 | 55 | 572 | 378 | 28 | 19 | 4 |
| Other Liabilities | 349 | 376 | 412 | 495 | 687 | 804 | 887 | 799 |
| Total Liabilities | 1.8k | 2.2k | 2.6k | 3.5k | 4.0k | 4.3k | 4.7k | 5.0k |
| AssetsFixed Assets | 651 | 634 | 1.3k | 1.9k | 2.0k | 2.0k | 2.0k | 1.9k |
| CWIP | 16 | 26 | 19 | 55 | 76 | 63 | 32 | 74 |
| Investments | 403 | 678 | 13 | 206 | 388 | 345 | 519 | 765 |
| Other Assets | 743 | 894 | 1.3k | 1.4k | 1.5k | 1.9k | 2.2k | 2.2k |
| Total Assets | 1.8k | 2.2k | 2.6k | 3.5k | 4.0k | 4.3k | 4.7k | 5.0k |
The Earnings Per Share over the last 12 months.
Your assumption of the company's expected yearly EPS growth (e.g., 6 for 6%).
Pre-filled with the lower of median (44.8×) and current (53.3×) PE — the conservative anchor.
The annualized return you aim to achieve. We solve for the price that delivers it, then compare to today's price.
At 20% growth and a 45× exit, ₹2409 only delivers your return if you pay ₹2,278. The price is currently baking in 21% growth.
EPS grows 20%/yr for 5 years, then fades to 6% over 2, exits at 45×.
| Year | Growth | EPS (₹) |
|---|---|---|
| FY27 | 20.0% | 54.20 |
| FY28 | 20.0% | 65.04 |
| FY29 | 20.0% | 78.05 |
| FY30 | 20.0% | 93.66 |
| FY31 | 20.0% | 112.40 |
| FY32 | 13.0% ·fade | 127.01 |
| FY33 | 6.0% ·fade | 134.63 |
Methodology: we discount normalized net profit as a proxy for owner earnings (an earnings-power approximation — not full free cash flow). Terminal growth is capped at 6% (≈ nominal GDP) regardless of the required return. This is an analytical tool, not investment advice.
Guides on how to read this kind of business and the numbers that matter.